Expert Perspectives & Insights into CAR T-cell Therapy in Relapsed / Refractory Acute Lymphoblastic Leukemia - Episode 6

Navigating CAR T-cell Therapy in R/R ALL: Expert Perspectives

July 11, 2024

Elias Jabbour, MD, Evandro D. Bezerra, MD, Lori Muffly, MD, Jae H. Park, MD, Gregory W. Roloff, MD

The panel examines the current positioning of CAR T-cell therapy within the treatment paradigm for Relapsed / Refractory Acute Lymphoblastic Leukemia, considering the distinctions between Philadelphia chromosome-positive and negative patients.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Overview of CAR T-cell Therapies in R/R B-cell ALL

EP. 2: CAR T-cell Therapy: Mechanisms of Actions of Brexucabtagene Autoleucel and Obecabtagene Autoleucel

EP. 3: Considerations for Dosing and Lymphodepletion with CAR T-cell Therapy in R/R ALL

EP. 4: Expert Perspectives on CAR T-Cell Therapy Logistics: Collection to Treatment

EP. 5: Overview of Available Treatment Options in R/R B-cell ALL

Now Viewing

EP. 6: Navigating CAR T-cell Therapy in R/R ALL: Expert Perspectives

EP. 7: Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data

EP. 8: Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL

EP. 9: Expert Perspectives on Bridging Therapy Strategies Prior to CAR T-cell Therapy

EP. 10: Sequencing Strategies with CAR T-cell Therapy in Patients with or without Prior Blinatumomab Treatment

EP. 11: Translating Data Updates from FELIX and ZUMA-3 to the Clinical Practice Setting

EP. 12: Expert Perspectives on the Potential Impact of Obe-cel on the Treatment Landscape for R/R ALL

EP. 13: Treatment Approaches with Consolidation and Maintenance Post CAR T-cell Therapy

EP. 14: Future Perspectives on CAR T-cell Therapy in R/R B-cell ALL

EP. 15: Frequency, Correlation with Clinical Outcomes, and Risk Factors for Severe CRS and ICANS in CAR T-cell Therapy

EP. 16: Expert Perspectives in Monitoring and Management Strategies for CRS, ICANS, and Other Long-Term Toxicities Associated with CAR T-cell Therapy

EP. 17: Logistical and Access Challenges with CAR T-cell Therapy in R/R ALL

EP. 18: Strategies and Resources for Overcoming Barriers to CAR T-Cell Therapy

EP. 19: Role of Multidisciplinary Team & Logistics of CAR T-cell Therapy Administration in the Inpatient or Outpatient Setting

EP. 20: Key Takeaways and Clinical Pearls in the Treatment of R/R ALL

Video content above is prompted by the following:

Where does CAR T-cell therapy currently fall in your treatment paradigm?
- Does it differ between patients who are Philadelphia positive vs. negative, or those with high-risk features, or extramedullary disease?
How does bulk of disease or percentage of blasts factor into your decision making?